Zavzpret Nasal Spray Approved for Acute Treatment of Migraine
The FDA has approved Zavzpret (zavegepant) nasal spray for the acute treatment of migraine with or without aura in adults.
Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has approved Zavzpret (zavegepant) nasal spray for the acute treatment of migraine with or without aura in adults.
[Editor’s Note: The High Cost of Risky Business: Lessons in Vigilance from Enron, Wirecard, and Silicon Valley Bank was first published March 15, 2023 on ComplexDiscovery and is...
Pluvicto is currently in shortage due to challenges in meeting demand and no therapeutic equivalents being available.
The FDA has accepted the sNDA for empagliflozin to improve glycemic control plus diet and exercise in patients aged ≥10 years with type 2 diabetes.
The FDA has accepted the sNDA for vosoritide for the treatment of children less than 5 years of age with achondroplasia.